Disease‐burden‐adapted immunotherapy protocol for primary refractory or high‐risk relapsed pediatric acute lymphoblastic leukemia
Authors:
Open Access
- 29 July 2024
- journal article
- letter
- Published by Wiley in HemaSphere
- Vol. 8 (8) , e111
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trialsEuropean Journal of Cancer, 2021
- Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic LeukemiaJAMA, 2021
- Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic LeukemiaJAMA, 2021
- Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?Biomarker Research, 2020
- How I treat relapsed acute lymphoblastic leukemia in the pediatric populationBlood, 2020
- Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemiaBlood Advances, 2019
- Efficacy and safety of a bortezomib and reduced‐intensity cytarabine‐based protocol, TMC ALLR1, for relapsed childhood ALL in IndiaBritish Journal of Haematology, 2019
- Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemiaLeukemia, 2018
- Flow Cytometric Monitoring for Residual Disease in B Lymphoblastic Leukemia Post T Cell Engaging Targeted TherapiesCurrent Protocols in Cytometry, 2018
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaNew England Journal of Medicine, 2018